SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-154675
Filing Date
2024-06-05
Accepted
2024-06-05 06:58:30
Documents
13
Period of Report
2024-06-05
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d839689d8k.htm   iXBRL 8-K 26183
  Complete submission text file 0001193125-24-154675.txt   151984

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alrn-20240605.xsd EX-101.SCH 2855
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20240605_lab.xml EX-101.LAB 18756
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20240605_pre.xml EX-101.PRE 11713
17 EXTRACTED XBRL INSTANCE DOCUMENT d839689d8k_htm.xml XML 3808
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 241020685
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)